A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Clinical trial NCT05266196 · UNKNOWN

Trial details

NCT number: NCT05266196
Sponsor: Salarius Pharmaceuticals, LLC
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ewing Sarcoma Myxoid Liposarcoma Desmoplastic Small Round Cell Tumor Extraskeletal Myxoid Chondrosarcoma Angiomatoid Fibrous Histiocytoma Clear Cell Sarcoma Myoepithelial Tumor Low Grade Fibromyxoid Sarcoma Sclerosing Epithelioid Fibrosarcoma

Start date: 2022-01-15
Primary completion: 2025-12-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.